Prior to the massive financial woes that helped "The Governator" take office in California, one of the state's most talked-about stories was a universal healthcare coverage proposal from Bruce Bodaken, chairman, CEO and president of Blue Shield of California (BSC). Other states, such as neighboring Oregon, have considered universal coverage plans in the past, but to date none have been implemented. Due to California's severe economic crisis, Bodaken's plan has been put on the back burner too. But it's still a much-discussed proposal in the state's healthcare circles, and once Gov. Schwarzenegger gets acclimated to his responsibilities and finds a way to stem the state's financial bleeding, it is expected to take center stage once again.
Innovations in Pharmacy and Its Impact on Managed Care
March 29th 2023Managing Directors of L.E.K. Consulting, Joe Johnson, Todd Clark and Brendan Mitchell introduce the innovations happening in pharmacy, more specifically disruptive innovations, and how they affect managed care. The team explained some of the innovations to be on the lookout for in the future, also.
Read More
The senior vice president of health services and chief medical officer at Independence Blue Cross in Philadelphia discusses the spotlight that the COVID-19 pandemic put on behavioral health and Independence's integration of behavioral health into its coverage and care management in this month's episode of “What's on Your Mind?" podcast.
Listen
What Reimbursable Remote Care Through New CMS CPT Codes Means For Patients
March 1st 2023Briana Contreras, an editor of Managed Healthcare Executive, chats with Bronwyn Spira, CEO and founder of Force Therapeutics, in this week's episode about CMS' new CPT codes that were introduced in 2022.
Listen
Gene Therapy for Hemophilia Is Becoming a Reality. Who Will Write the Checks to Pay for It?
March 27th 2023Hemgenix for hemophilia B is priced to cost $3.5 million per treatment. Roctavian for hemophilia A may be approved by the FDA in July and is likely to be priced to cost between $2 million and $3 million per treatment.
Read More
FDA Updates for the Week of March 20, 2023
March 25th 2023FDA approvals this week include: novel treatment for invasive candidiasis, an accelerated approval to Zynyz for Merkel cell carcinoma, the high-concentration Humira biosimilar Hyrimoz, and extension of Evkeeza’s indication to include young children. The agency also issued two complete responses this week: for Incyte’s extended-release Jakafi and for AbbVie’s Parkinson’s therapy.
Read More
2 Clarke Drive
Cranbury, NJ 08512